Insights

Why Policy, Not Science, is the New Bottleneck

The biopharmaceutical sector entered 2025 with an unprecedented level of liquidity, with dry powder estimates exceeding $1.5 trillion across top tier pharma companies.

The pharmaceutical patent cliff refers to the wave of blockbuster drugs whose patent protections are expiring, exposing their makers to competition from generics and biosimilars. Industry analysts warn that by the end of this decade, over $200 billion in annual revenues is  at risk as dozens of best blockbusters lose exclusivity.

The field of antibody-drug conjugates has transitioned from a promising therapeutic concept to a validated, cornerstone modality in modern oncology.

Licensing partnerships have become a critical strategy for biopharma companies to fuel their  pipeline, especially as blockbuster drugs approach patent expiration. In 2024.  Big Pharma has significantly ramped up spending on licensing deals,  investing on average 33% in 2024 more than in 2023,  to access novel therapies and mitigate the looming “patent cliff”. With top selling drugs like  Keytruda  and  Eliquis  set to lose exclusivity by 2028, big pharmas are turning to biotechs for licensing deals with massive potential to fill anticipated revenue gaps.

In BioPharma the R&D pipeline often mirrors the dynamics of financial markets. It is fractal and in certain targets you will see what appears to be crowded positioning, meaning there are many individuals/institutions/companies going after the same target.